He is the former Representative Director of Watervein Partners. He has been Outside Director of KinoPharma since 2006 and was appointed CEO in December 2010.
He has experience in investing and incubating a number of biotech startup companies in Japan (OncoTherapy Science, HuBit Genomix, Anaeropharma Science, Himuka AM Pharma, etc.).
Ex-JST/START program promoter. He holds an MBA.
After working as a researcher of CREST and NEDO, he became a Specially-appointed Research Associate of Kurokawa Laboratory at The Institute of Medical Sciences, Tokai University in 2003.
He founded KinoPharma and was appointed COO in 2005. Since then, as the Leader of Drug Discovery Program, he has been engaged in activities, ranging from platform technologies to development.
(in charge of business strategy)
He had been engaged in drug discovery at Chugai Pharmaceutical. He changed his careers to venture capital and served as the Deputy General Manager of Lifescience at Mitsubishi UFJ Capital. He served as Outside Director of KinoPharma from 2013 to June 2015. He concurrently serves as the director of Anicom capital and KinoPharma from January 2016. He holds a PhD.
(in charge of research planning, quality assurance, and risk management)
He is the former director of Biology Research Institute, director of Safety Research Institute, and deputy director of Exploratory Research Institute at JT Pharmaceutical Department. He has an extensive experience, ranging from exploratory research to safety studies. He has a PhD.
He has been engaged in clinical development at Chugai Pharmaceutical. He was appointed as the Director of Clinical Development of Chugai Pharmaceutical in 2005. He was appointed President of Chugai Pharma Science (Beijing) in 2011 and has been served as an outside director of KinoPharma since January 2018.
After working at Deutsche Securities and TPG Capital, he joined Japan Growth Investments Alliance as a director (current position) in 2017. He has been serving as an outside director of KinoPharma since September 2018.